Sensitivity (95% CI) | Specificity (95% CI) | Positive predictive value (95% CI) | Negative predictive value (95% CI) | Likelihood ratio | |
MDA | 0.96 (0.87 to 0.99) | 0.46 (0.32 to 0.61) | 0.67 (0.55 to 0.77) | 0.92 (0.73 to 0.99) | 1.8 |
VLDA | 1 (0.82 to 1) | 0.35 (0.22 to 0.48) | 0.30 (0.18 to 0.44) | 1 (0.80 to 1) | 1.6 |
DAPSA low disease activity | 0.81 (0.66 to 0.91) | 1 (0.81 to 1) | 1 (0.9 to 1) | 0.69 (0.48 to 0.85) | – |
DAPSA remission | 1 (0.76 to 1) | 0.38 (0.24 to 0.53) | 0.32 (0.19 to 0.48) | 1 (0.81 to 1) | 1.62 |
PsAID ≤4 | 0.79 (0.65 to 0.89) | 0.77 (0.52 to 0.93) | 0.90 (0.77 to 0.97) | 0.58 (0.36 to 0.77) | 3.5 |
HAQ-DI ≤0.5 | 0.86 (0.74 to 0.93) | 0.68 (0.43 to 0.87) | 0.89 (0.78 to 0.95) | 0.61 (0.38 to 0.81) | 2.7 |
DPASA, disease activity score for psoriatic arthritis; HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; PASS, Patient’s acceptable symptom state; PsAID, Psoriatic arthritis impact of disease; VLDA, very low disease activity.